Financials · Security & Commodity Brokers, Dealers, Exchanges & Services

CME CME Group SEC Filings & Insider Trading Activity 2026

company
CIK 1156375110 filings
S&P 500

CME at a glance

CME Group (CME, SEC CIK 1156375) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 21, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CME Group (CME) reported revenue of $6.5 billion (up 6.4% from FY2024) and net income of $4.1 billion. Diluted EPS was $11.16.
  • As of September 30, 2026, 55 institutional investment managers tracked by SignalX reported holding CME Group (CME) shares worth $38.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by DUFFY TERRENCE A on November 18, 2026 of 10,000 shares at $308.54 per share.
  • In the last 90 days, CME insiders reported 1 open-market purchase ($79K) and 11 open-market sales ($18.3M) on Form 4, a net sale of $18.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.5B
+6.4% vs prior year
Insiders · 90 days
1 buy · 11 sells
Net −$18.2M
13F holders
55 funds
$38.6B · −3 vs prior quarter
Latest 8-K
Oct 21, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Global derivatives exchange operator: trading, clearing, and data services across interest rates, equities, FX, commodities, and crypto
  • Two new 2025 platform launches: BrokerTec Chicago (second CLOB for cash U.S. Treasuries co-located with futures) and FX Spot+ (connects OTC spot FX with futures liquidity)
  • CMESC received SEC approval in December 2025 to become a securities clearing agency, targeting U.S. Treasury (Dec 2026) and repo (June 2027) clearing mandates
  • Record ADV of 28.1 million contracts in 2025; micro products +32% YoY, Asia Pacific trading hours volume +13% YoY
  • Joint venture with FanDuel (Flutter Entertainment) launched December 2025: retail prediction markets app covering financial, economic, and sporting event contracts

Risk Factors

  • FMX Futures Exchange and prediction market platforms (via FanDuel JV) directly targeting CME's derivatives and event-contract segments; litigation ongoing across multiple jurisdictions
  • Basel III Endgame and potential GSIB capital surcharge changes could raise bank clearing firm capital requirements, reducing their trading activity in CME markets
  • CyrusOne data center cooling failure (November 27, 2025) forced temporary market halt; single largest data center represents unhedged operational concentration
  • $3.4B total debt outstanding as of December 31, 2025, with $2.3B additional borrowing capacity; fixed-cost structure amplifies earnings risk in low-volume environments
  • 85% of 2025 derivatives contract volume from members holding board seats and conflicting economic interests vs. Class A shareholders

Management Discussion & Analysis

  • Revenue $6,520.6M in 2025, up ~6.4% YoY from $6,130.1M; clearing & transaction fees $5,281.1M (+5.9%), market data $803.1M (+13.1%)
  • Operating margin 64.9% vs 64.1% in 2024; net income $4,072.2M vs $3,525.8M; diluted EPS $11.16 vs $9.67
  • Best segment: market data +$92.9M YoY; contract volume up 5.6% to 7,060.4M driven by interest rates (+3.6%) and equity indexes (+8.2%); FX weakest, volume down ~5%
  • Operating cash flow $4,277.1M vs $3,690.5M; capex guided ~$85M for 2026; $2.7B remaining under $3.0B buyback authorization; variable dividend $6.15/share plus quarterly $1.30/share declared Feb 2026
  • Key risks: tariff uncertainty, Fed rate policy, competitive intensity; OSTTRA JV sold in Q4 2025 generating $306.1M gain; Google Cloud transformation ongoing with shifting cost profile

AI summary of the CME 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Carried-forward risks remain the principal regulatory, operational, market and financial exposures identified in the 10-K

Management Discussion & Analysis

  • Revenue $1,737.3M, up from $1,537.6M YoY, with clearing and transaction fees $1,378.1M vs $1,227.9M
  • Operating margin 65.7% vs 63.3% YoY, net income $1,036.9M vs $908.0M
  • Strongest product line: interest rates, average daily volume 15,121 vs 13,378 thousand
  • Weakest product line: cryptocurrency, contract volumes decreased versus the third quarter of 2025
  • Operating cash flow $3,292.9M vs $3,143.2M, cash $2.2B vs $4.4B at December 31, 2025, share repurchase authorization remaining $1.0B

AI summary of the CME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 21, 2026Full analysis →

Item EX-99.19: Item EX-99.19

  • Q3 2026 revenue reached a record $1.7B, up from $1.5B, with net income rising to $1.0B
  • Adjusted diluted EPS $3.02 versus $2.68, highlighting earnings growth beyond reported GAAP results

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026, released October 21, 2026
  • Exhibit 99.1 contains CME’s financial results and investor-relevant operating performance details
Filed Sep 25, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Series G Non-Voting Convertible Preferred Stock designation eliminated effective September 24, 2026
  • No Series G shares outstanding, limiting direct shareholder impact
Filed Sep 9, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jack Tobin named Deputy CFO November 2, 2026, then CFO in March 2027
  • Planned retirement deferred, preserving finance leadership continuity through succession

Item EX-99.1: Item EX-99.1

  • Jack Tobin becomes CFO in March 2027, succeeding Lynne Fitzpatrick as she becomes CEO
  • Tobin becomes Deputy CFO in November 2026, supporting an extended finance leadership transition

AI summaries of CME 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CME

Don't miss the next CME filing

  • Alerts as it files. A push when CME files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CME, by share count.
  • Ask anything. An AI agent that reads every CME filing and answers with sources.

CME alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DUFFY TERRENCE ASellNov 18, 2026$308.54
DUFFY TERRENCE ASellNov 18, 2026$310.18
Marchese John CliffordSellNov 18, 2026$310.75
Kaye Daniel GSellNov 9, 2026$304.17
SIEGEL HOWARD JSellNov 2, 2026$303.00
Winkler JulieSellNov 2, 2026$305.15
Cutinho SunilSellOct 27, 2026$298.70
GEPSMAN MARTIN JSellOct 22, 2026$302.50

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$6.1B$6.5B
Operating Income$3.4B$3.9B$4.2B
Net Income$3.2B$3.5B$4.1B
Op. Margin-64.1%64.9%
Net Margin-57.5%62.5%
Balance Sheet
Total Assets-$137.4B$198.4B
Equity-$26.5B$28.7B
ROE-13.3%14.2%
Per Share
EPS-$9.67$11.16
Cash Flow
Operating CF$3.5B$3.7B$4.3B
CapEx$76.4M$94.0M$83.5M

Source: XBRL data in CME Group (CME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CME share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CME shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202655$38.56B
Q2 202658$32.38B
Q1 202655$45.16B
Q4 202551$40.63B
Q3 202554$43.65B
Q2 202551$42.60B
Q1 202548$31.04B
Q4 202446$20.72B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 418 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CME filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 10, 2026--
4Nov 3, 2026--
4Nov 2, 2026--
4Oct 27, 2026--
10-QOct 23, 2026Analysis
4Oct 22, 2026--
8-KOct 21, 2026Analysis-
4Sep 28, 2026--
8-KSep 25, 2026Analysis-
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 14, 2026--
4Sep 11, 2026--
8-KSep 9, 2026Analysis-

Related Financials companies

All Financials →

CME SEC filings: frequently asked questions

Are CME insiders buying or selling?

In the last 90 days, CME Group (CME) officers, directors and 10% owners reported 1 open-market purchase worth $78,626 by 1 insider and 11 open-market sales worth $18.3 million by 8 insiders on Form 4, a net sale of $18.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CME stock?

As of September 30, 2026, the largest CME Group (CME) holders among the 13F filers tracked by SignalX were BlackRock ($7.9 billion), Vanguard Capital Management LLC ($6.2 billion), State Street Corp ($4.3 billion), Morgan Stanley ($2.7 billion), Vanguard Portfolio Management LLC ($2.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CME's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CME Group (CME) reported revenue of $6.5 billion (up 6.4% from FY2024) and net income of $4.1 billion. Diluted EPS was $11.16. The figures come from the XBRL data in the 10-K.

What are the main risks in CME's latest 10-K?

In the 10-K filed February 26, 2026, CME Group (CME) flagged: FMX Futures Exchange and prediction market platforms (via FanDuel JV) directly targeting CME's derivatives and event-contract segments; litigation ongoing across multiple jurisdictions. Basel III Endgame and potential GSIB capital surcharge changes could raise bank clearing firm capital requirements, reducing their trading activity in CME markets. (AI summary of the Risk Factors section.)

What did CME report in its latest 8-K?

CME Group (CME) filed an 8-K on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 revenue reached a record $1.7B, up from $1.5B, with net income rising to $1.0B.

What are the latest CME SEC filings?

CME Group (CME) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 21, 2026 and a Form 4 insider filing on November 19, 2026.

What is CME's SEC CIK number?

CME Group (CME)'s SEC Central Index Key (CIK) is 1156375. EDGAR lists every CME filing under that number.

Ask anything about CME

The research agent reads CME's filings, financials, insider trades and 13F holders, then answers with sources.